27 April 2018 in Clinical and Translational Medicine
Lipidomics is a measurement of a large scale of lipid species to understand roles of their carbon atoms, dual bonds, or isomerism in the lipid molecule. Clinical lipidomics was recently defined “as a new integrative biomedicine to discover the correlation and regulation between a large scale of lipid elements measured and analyzed in liquid biopsies from patients with those patient phenomes and clinical phenotypes”. The first step to translate lipidomics into clinical lipidomics is to settle a number of standard operation procedures and protocols of lipidomics performance and measurement. Clinical lipidomics is the part of clinical trans‐omics which was coined as a new emerging scientific discipline where clinical phenomes are integrated with molecular multiomics. We believe it is the time to translate lipid science and lipidomics into clinical application and to understand the importance of clinical lipidomics as one of the most helpful approaches during the design and decision‐making of therapeutic strategies for individuals. We emphasize here that clinical lipidomics should be merged with clinical phenomes, e.g. patient signs and symptoms, biomedical analyses, pathology, images, and responses to therapies, although it is difficult to integrate and fuse the information of clinical lipidomics with clinical phenomes. It will be a great achievement if we can draw the networks of lipidomic species fused with networks of genes and proteins to describe the molecular mechanisms of the disease in multi‐dimensions.
13 January 2023 in Clinical and Translational Medicine
Lung cancer is a widespread malignancy with a high death rate and disorder of lipid metabolism. Lysophosphatidylcholine (lysoPC) has anti‐tumour effects, although the underlying mechanism is not entirely known. The purpose of this study aims at defining changes in lysoPC in lung cancer patients, the effects of lysoPC on lung cancer cells and molecular mechanisms. Lung cancer cell sensitivity to lysoPC was evaluated and decisive roles of long‐chain acyl‐coenzyme A synthase 5 (ACSL5) in lysoPC regulation were defined by comprehensively evaluating transcriptomic changes of ACSL5‐downregulated epithelia. ACSL5 over‐expressed in ciliated, club and Goblet cells in lung cancer patients, different from other lung diseases. LysoPC inhibited lung cancer cell proliferation, by inducing mitochondrial dysfunction, altering lipid metabolisms, increasing fatty acid oxidation and reprograming ACSL5/phosphoinositide 3‐kinase/extracellular signal‐regulated kinase‐regulated triacylglycerol‐lysoPC balance. Thus, this study provides a general new basis for the discovery of reprogramming metabolisms and metabolites as a new strategy of lung cancer precision medicine.
9 August 2021 in Clinical and Translational Medicine
Mitochondrial dysfunction contributes to the imbalance of cellular homeostasis and the development of diseases, which is regulated by mitochondria‐associated factors. The present review aims to explore the process of the mitochondrial quality control system as a new source of the potential diagnostic biomarkers and/or therapeutic targets for diseases, including mitophagy, mitochondrial dynamics, interactions between mitochondria and other organelles (lipid droplets, endoplasmic reticulum, endosomes, and lysosomes), as well as the regulation and posttranscriptional modifications of mitochondrial DNA/RNA (mtDNA/mtRNA). The direct and indirect influencing factors were especially illustrated in understanding the interactions among regulators of mitochondrial dynamics. In addition, mtDNA/mtRNAs and proteomic profiles of mitochondria in various lung diseases were also discussed as an example. Thus, alternations of mitochondria‐associated regulators can be a new category of biomarkers and targets for disease diagnosis and therapy.
1 March 2020 in Clinical and Translational Medicine
A new coronavirus SARS‐CoV‐2 has caused outbreaks in multiple countries and the number of cases is rapidly increasing through human‐to‐human transmission. Clinical phenomes of patients with SARS‐CoV‐2 infection are critical in distinguishing it from other respiratory infections. The extent and characteristics of those phenomes varied depending on the severities of the infection, for example, beginning with fever or a mild cough, progressed with signs of pneumonia, and worsened with severe or even fatal respiratory difficulty in acute respiratory distress syndrome. We summarized clinical phenomes of 3795 patients with COVID‐19 based on 80 published reports from the onset of outbreak to March 2020 to emphasize the importance and specificity of those phenomes in diagnosis and treatment of infection, and evaluate the impact on medical services. The data show that the incidence of male patients was higher than that of females and the level of C‐reaction protein was increased as well as most patients' imaging included ground‐glass opacity. Clinical phenomes of SARS‐CoV‐2 infection were compared with those of SARS‐CoV and MERS‐CoV infections. There is an urgent need to develop an artificial intelligence‐based machine learning capacity to analyze and integrate radiomics‐ or imaging‐based, patient‐based, clinician‐based, and molecular measurements‐based data to fight the outbreak of COVID‐19 and enable more efficient responses to unknown infections in future.
15 May 2023 in Clinical and Translational Discovery
The deregulation of the metabolic network of cancer cells is now considered one of the characteristics of cancer. Aberrant lipid synthesis and additional lipid intake promote the rapid proliferation of cancer cells. In mammals, there are five members of the long‐chain acyl‐CoA synthase family involved in de novo lipid synthesis, fatty acid (FA) degradation and subsequent membrane modification. Their main function is to activate long‐chain FAs through the CoA chain link, and these conjugates are mainly used for the synthesis of triglycerides. In a variety of cancers, the expression of long‐chain acyl‐CoA synthetases (ACSLs) is different, and it also changes in different cancer subtypes. This review summarized recent research on the biological functions of ACSL, as well as recent advances in related diseases, and explored the potential therapeutic role of ACSL genes.